1. Home
  2. GRML vs LUNG Comparison

GRML vs LUNG Comparison

Compare GRML & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GRML

Greenland Mines Ltd. Common Stock

N/A

Current Price

$0.29

Market Cap

51.5M

Sector

N/A

ML Signal

N/A

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.55

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRML
LUNG
Founded
N/A
1995
Country
United States
United States
Employees
5
N/A
Industry
Industrial Specialties
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
51.5M
57.9M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
GRML
LUNG
Price
$0.29
$1.55
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$5.38
AVG Volume (30 Days)
3.6M
328.0K
Earning Date
05-13-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
N/A
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.01
52 Week Low
$0.27
$1.13
52 Week High
$0.55
$3.88

Technical Indicators

Market Signals
Indicator
GRML
LUNG
Relative Strength Index (RSI) 31.38 54.56
Support Level $0.27 $1.39
Resistance Level $0.44 $1.67
Average True Range (ATR) 0.04 0.12
MACD -0.01 -0.00
Stochastic Oscillator 11.11 54.94

Price Performance

Historical Comparison
GRML
LUNG

About GRML Greenland Mines Ltd. Common Stock

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: